IPCOR aims to improve prostate cancer outcomes and maximise patient quality of life
by feeding information back to hospitals and policymakers for quality improvement initiatives
About IPCOR
The Irish Prostate Cancer Outcomes Research is establishing a nationwide prostate cancer registry which captures high-quality information from newly diagnosed prostate cancer patients in the Republic of Ireland.
About IPCOR
Our Goals
Our main objective is to collect detailed clinical and quality of life data on Irish men’s prostate cancer journey to better inform future care delivery, knowledge of the disease and best use of health care innovations and resources.
About IPCOR
Research
In order to improve prostate cancer care, IPCOR will publish reports with a high level of clinical information and sophisticated data analysis. These reports will be published annually and delivered to service providers and decision makers in healthcare.
About IPCOR
What is the Irish Prostate Cancer Outcomes Research?
IPCOR created the first national prostate cancer registry in Ireland. This registry contains clinical and quality of life data on 6816 men who were diagnosed with prostate cancer and treated in 16 hospitals around Ireland between 2016 and 2020.
The registry has now been renewed with improved processes and technology for prospective data collection.
The IPCOR registry has now returned
as a clinical quality and outcomes registry
to collect longitudinal clinical data on men undergoing diagnosis and treatment for prostate cancer. Along with clinical data and quality of life measures including patient reported outcomes measurements (PROMs), IPCOR has also established a biorepository for blood and urine samples of men who consent to participate, as well as access to their routine prostate tissue. In the first phase of this second edition, IPCOR will be operational at 5 major hospital sites in Dublin and Galway.
What's Important about Prostate Cancer?
Over 4,000 men are diagnosed with prostate cancer each year in Ireland, and one in six men will be diagnosed with it during their lifetime
The prostate is a small gland that lies below your bladder. If there is an enlargement or abnormal growth in this gland it can press on the tube that carries urine and cause symptoms.
Even before symptoms develop, an elevated PSA (prostate-specific antigen) test can be a sign that your prostate needs to be investigated. Early detection can save lives and prevent adverse effects of treatment that may reduce quality of life of the affected individual.
Funding
IPCOR is a Movember funded project
It is managed and owned by the School of Medicine, University College Dublin (UCD). The Principal Investigator of IPCOR is Associate Clinical Professor David Galvin, Consultant Urologist.
